Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Erlotinib + Gemcitabine|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Erlotinib||Tarceva||CP358774||EGFR Inhibitor (Pan) 46 EGFR Inhibitor 1st gen 3||Tarceva (erlotinib) is a first-generation EGFR inhibitor, which is FDA approved for non-small cell lung carcinoma patients with EGFR exon 19 deletions and/or EGFR L858R and in combination with gemcitabine for patients with advanced pancreatic cancer (FDA.gov; PMID: 25302162).|
|Gemcitabine||Gemzar||Difluorodeoxycytidine Hydrochlorothiazide|LY-188011||Chemotherapy - Antimetabolite 11||Gemzar (gemcitabine) is converted in cells to difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP), which act to inhibit ribonucleoside reductase and as a deoxynucleotide analog respectively, resulting in DNA strand termination and apoptosis (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||pancreatic cancer||not applicable||Erlotinib + Gemcitabine||FDA approved||Actionable||In a Phase III clinical trial that supported FDA approval, the combination of Tarceva (erlotinib) and Gemzar (gemicitabine) resulted in an improved median overall survival of 6.24 months compared to 5.91 months with Gemzar (gemicitabine) and placebo, and prolonged progression-free survival (HR=0.77 (95% CI, 0.64 to 0.92; P = .004)) in patients with advanced pancreatic cancer (PMID: 17452677).||17452677 detail...|
|CBL dec exp||pancreatic ductal carcinoma||predicted - sensitive||Erlotinib + Gemcitabine||Preclinical - Cell line xenograft||Emerging||In a preclinical study, addition of Tarceva (erlotinib) overcame Gemzar (gemcitabine)-resistance in pancreatic ductal carcinoma cell lines with reduced Cbl expression via shRNA, resulted in decreased viability in cell culture and reduced tumor growth in cell line xenograft models (PMID: 25348515).||25348515|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02154737||Phase I||Erlotinib + Gemcitabine||Gemcitabine and Pulse Dose Erlotinib in Second Line Treatment of Advanced Pancreatic Cancer||Active, not recruiting|
|NCT01013649||Phase II||Erlotinib + Gemcitabine Gemcitabine||Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery||Active, not recruiting|